The ALDH3A1 Knockout A-549 Polyclonal Cells product comprises a polyclonal population of the human lung adenocarcinoma cell line A-549 with CRISPR/Cas9-mediated disruption of the aldehyde dehydrogenase 3A1 (ALDH3A1) gene. This loss-of-function model is generated from a heterogeneous pool of edited cells, providing a physiologically relevant system to interrogate the roles of ALDH3A1 without selection for a single clonal genotype. The polyclonal format preserves cellular diversity, which can better recapitulate tumor heterogeneity in downstream functional assays.
Derived from a human lung adenocarcinoma, the A-549 cell line is an epithelial model widely employed in cancer biology, drug metabolism, and respiratory disease research. Originating from the alveolar epithelium of a 58-year-old male, A-549 cells are adherent, exhibit rapid proliferation, and retain key characteristics of type II pneumocytes. Their robust growth and extensive characterization make them an ideal host for gene-editing studies focused on oxidative stress, xenobiotic detoxification, and oncogenic signaling.
ALDH3A1 functions as a critical detoxification enzyme, catalyzing the NAD(P)+-dependent oxidation of a broad spectrum of aldehyde substrates, including lipid peroxidation products such as 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA). The protein homodimerizes and is transcriptionally regulated by the oxidative stress-responsive transcription factor NFE2L2 (Nrf2), as well as by the aryl hydrocarbon receptor (AHR) and electrophilic compounds. Downstream, ALDH3A1 activity reduces the intracellular pool of reactive aldehydes, thereby attenuating lipid peroxidation-driven cascades, preserving cellular redox balance, and limiting oxidative DNA damage. In the A-549 lung adenocarcinoma background, this enzyme is often overexpressed and contributes to the detoxification of chemotherapeutic agents, linking its activity to acquired chemoresistance.
Disruption of ALDH3A1 in A-549 polyclonal cells impairs the clearance of cytotoxic aldehydes, sensitizing the cells to oxidative insults and elevating basal reactive oxygen species (ROS) levels. This alteration creates a vulnerability that can be exploited to dissect the molecular mechanisms of chemoresistance and identify synthetic lethal interactions. The model is particularly valuable for evaluating the role of aldehyde metabolism in shaping the cancer stem cell phenotype, as ALDH3A1 activity is often associated with stem-like characteristics in lung adenocarcinoma. Moreover, deficiencies in this enzyme cascade can amplify DNA damage and apoptosis triggered by platinum-based drugs such as cisplatin, making these cells a robust platform for studying treatment resistance and testing novel combination therapies.
Researchers can employ these polyclonal knockout cells in a variety of experimental paradigms, including flow cytometric assessment of ALDH activity using ALDHEFLUOR, quantitative immunoblotting and RT-qPCR for pathway validation, and functional assays such as DCFDA-based ROS measurement, MTT/resazurin viability assessments, and cisplatin sensitivity testing. The comet assay further allows detection of oxidative DNA damage accumulation. Applications span investigations into chemoresistance mechanisms, oxidative stress biology, lung adenocarcinoma progression, cancer stem cell biomarker studies, and toxicological screening of aldehyde-generating compounds. For further details on experimental validation and culture protocols, please contact Ascent Research.
